|
|
||||||||
University of Milan, Milan, Department of Thoracic Surgery, European Institute of Oncology, Via Ripamonti 435, Milan, 20141 Italy
(Email: lorenzo.spaggiari@ieo.it).
| The first 20% of the full text of this article appears below. |
The article by Farjah and colleagues [1] is very interesting, and two aspects are relevant; on one hand, only 9% of patients affected by T4 nonsmall cell lung cancer (NSCLC) are eligible for lung resection; on the other, survival of a carefully selected group of patients may be very promising (5 yrs > 40%).
Patients affected by T4 NSCLC present a heterogeneous disease that is often associated with bulky lympho-nodal involvement; concurrent or sequential chemoradiotherapy represents the gold standard treatment, but 5-year survival is less than 10%.
"T4 multiple nodular" disease is a different oncological entity that does not require complex surgical procedures and that has a different oncological impact from "T4 mediastinal" disease. This group of T4 NSCLC (multiple
Related Article
Ann. Thorac. Surg. 2008 86: 368-374.
This article has been cited by other articles:
![]() |
L. Spaggiari Invited commentary. Ann. Thorac. Surg., August 1, 2009; 88(2): 397 - 398. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |